Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Famotidine
- Accession Number
- DB00927 (APRD00296)
- Type
- Small Molecule
- Groups
- Approved
- Description
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem]
- Structure
Structure for DB00927 (Famotidine)
- Synonyms
- (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
- 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
- 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
- Famotidina
- Famotidinum
- N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
- External IDs
- L 643341 / MK-208 / YM-11170
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Bci Famotidine Tablet 40 mg Oral Baker Cummins Inc Not applicable Not applicable Canada 
Bci Famotidine Tablet 20 mg Oral Baker Cummins Inc Not applicable Not applicable Canada Famotidine Powder, for suspension 40 mg/5mL Oral Paddock Laboratories, Inc. 2010-05-28 2017-10-26 US 
Famotidine 10mg Tablet 10 mg Oral Laboratoire Riva Inc Not applicable Not applicable Canada Famotidine Injection Solution 10 mg Intravenous Mylan Pharmaceuticals Not applicable Not applicable Canada Famotidine Injection Solution 10 mg Intravenous Fresenius Kabi Not applicable Not applicable Canada Famotidine Injection Solution 10 mg Intravenous Hospira, Inc. Not applicable Not applicable Canada Famotidine Injection Solution 10 mg Intravenous Mylan Pharmaceuticals Not applicable Not applicable Canada Famotidine IV Injection Solution 10 mg Intravenous Teva Not applicable Not applicable Canada Famotidine IV Injection Solution 10 mg Intravenous Teva Not applicable Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-famotidine Injectable Solution 10 mg Intravenous Apotex Corporation 2003-11-17 2013-08-02 Canada Apo-famotidine Injectable Solution 10 mg Intravenous Apotex Corporation 2004-05-27 2013-08-02 Canada Apo-famotidine Tab 20mg USP Tablet 20 mg Oral Apotex Corporation 1993-12-31 Not applicable Canada Apo-famotidine Tab 40mg USP Tablet 40 mg Oral Apotex Corporation 1993-12-31 Not applicable Canada Famotidine Tablet 20 mg/1 Oral North Star Rx Llc 2009-07-01 2016-10-13 US Famotidine Injection 10 mg/mL Intravenous West Ward Pharmaceutical 2001-04-16 Not applicable US Famotidine Tablet, film coated 20 mg/1 Oral Cardinal Health 2009-06-10 2017-11-04 US Famotidine Tablet, film coated 20 mg/1 Oral Remedy Repack 2017-04-25 Not applicable US Famotidine Tablet, film coated 40 mg/1 Oral Mylan Pharmaceuticals 2001-04-16 Not applicable US 
Famotidine Tablet 20 mg/1 Oral Mc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation 2009-07-01 2017-01-05 US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 7 Select Acid Controller Tablet 20 mg/1 Oral 7 Eleven 2014-08-05 Not applicable US Acid Control Tablet 20 mg Oral Apotex Corporation 2014-04-28 Not applicable Canada Acid Control Tablet 10 mg Oral Vita Health Products Inc 1998-10-27 Not applicable Canada Acid Control Tablet 10 mg Oral Pendopharm Division Of De Pharmascience Inc 1997-09-08 2015-01-19 Canada Acid Control Tablet 10 mg Oral Teva 1997-06-17 Not applicable Canada Acid Control Tablet 10 mg Oral Apotex Corporation 2000-07-11 Not applicable Canada Acid Control Original Strength Tablet 10 mg/1 Oral Medicine Shoppe International 2009-10-19 2017-11-30 US Acid Controller Tablet 20 mg/1 Oral Shopko Stores Operating 2013-07-17 Not applicable US Acid Controller Tablet 20 mg/1 Oral Walgreen 2006-09-26 Not applicable US Acid Controller Tablet 20 mg/1 Oral H.E.B. 2016-09-14 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acid Controller Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2013-06-05 2017-11-29 US Acid Controller Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2013-06-05 2017-11-29 US Acid Controller Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Safeway 2008-08-06 2017-12-22 US Acid Controller Complete dual action Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen 2008-07-30 Not applicable US Acid Controller Complete dual action Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen 2008-07-30 2018-03-29 US Acid Reducer Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2016-01-06 Not applicable US Acid Reducer Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen 2016-01-29 Not applicable US Acid Reducer Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Rite Aid 2009-05-15 2018-04-01 US Acid Reducer Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Shopko Stores Operating 2016-01-12 Not applicable US Acid Reducer Complete Famotidine (10 mg/1) + Calcium Carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1) Tablet, chewable Oral Walgreen 2016-01-29 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Famotidine Famotidine (2 mg/mL) Injection, solution Intravenous Cantrell Drug Company 2014-06-11 Not applicable US - International/Other Brands
- Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Fluxid / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal
- Categories
- Acid Reducers
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Gastrointestinal Agents
- Histamine Agents
- Histamine Antagonists
- Histamine H2 Antagonists
- Neurotransmitter Agents
- OAT3 Substrates
- Potential QTc-Prolonging Agents
- QTc Prolonging Agents
- Sulfur Compounds
- Thiazoles
- UNII
- 5QZO15J2Z8
- CAS number
- 76824-35-6
- Weight
- Average: 337.445
Monoisotopic: 337.044934829 - Chemical Formula
- C8H15N7O2S3
- InChI Key
- XUFQPHANEAPEMJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
- IUPAC Name
- 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
- SMILES
- NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1
Pharmacology
- Indication
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD).
- Associated Conditions
- Pharmacodynamics
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.
- Mechanism of action
Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
Target Actions Organism AHistamine H2 receptor antagonistHuman - Absorption
The bioavailability of oral doses is 40-45%.
- Volume of distribution
- Not Available
- Protein binding
15-20%
- Metabolism
Hepatic.
- Route of elimination
Renal clearance is 250-450 mL/min, indicating some tubular excretion.
- Half life
2.5-3.5 hours
- Clearance
- renal cl=250-450 mL/min
- Toxicity
Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Famotidine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Famotidine. Experimental, Illicit 2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Famotidine. Experimental 3,4-Methylenedioxyamphetamine 3,4-Methylenedioxyamphetamine may decrease the sedative activities of Famotidine. Experimental, Illicit 4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Famotidine. Experimental, Illicit Abiraterone The metabolism of Famotidine can be decreased when combined with Abiraterone. Approved Amiodarone Famotidine may increase the QTc-prolonging activities of Amiodarone. Approved, Investigational Amphetamine Amphetamine may decrease the sedative activities of Famotidine. Approved, Illicit, Investigational Anagrelide Famotidine may increase the QTc-prolonging activities of Anagrelide. Approved Apalutamide The serum concentration of Famotidine can be decreased when it is combined with Apalutamide. Approved, Investigational Armodafinil The metabolism of Famotidine can be decreased when combined with Armodafinil. Approved, Investigational Arsenic trioxide Famotidine may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Famotidine may increase the QTc-prolonging activities of Artemether. Approved Asenapine Famotidine may increase the QTc-prolonging activities of Asenapine. Approved Atazanavir The serum concentration of Atazanavir can be decreased when it is combined with Famotidine. Approved, Investigational Azithromycin Famotidine may increase the QTc-prolonging activities of Azithromycin. Approved Bedaquiline Famotidine may increase the QTc-prolonging activities of Bedaquiline. Approved Benzphetamine Benzphetamine may decrease the sedative activities of Famotidine. Approved, Illicit Benzylpenicilloyl Polylysine Famotidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent. Approved Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Famotidine. Approved, Investigational Bortezomib The metabolism of Famotidine can be decreased when combined with Bortezomib. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be decreased when it is combined with Famotidine. Approved Carbamazepine The metabolism of Famotidine can be increased when combined with Carbamazepine. Approved, Investigational Cefditoren The serum concentration of Cefditoren can be decreased when it is combined with Famotidine. Approved, Investigational Cefpodoxime Famotidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Cefuroxime Famotidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ceritinib Famotidine may increase the QTc-prolonging activities of Ceritinib. Approved Chloramphenicol The metabolism of Famotidine can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chloroquine Famotidine may increase the QTc-prolonging activities of Chloroquine. Approved, Investigational, Vet Approved Chlorphentermine Chlorphentermine may decrease the sedative activities of Famotidine. Illicit, Withdrawn Chlorpromazine Famotidine may increase the QTc-prolonging activities of Chlorpromazine. Approved, Investigational, Vet Approved Cholecalciferol The metabolism of Famotidine can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Famotidine can be decreased when combined with Cimetidine. Approved, Investigational Ciprofloxacin Famotidine may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride Famotidine may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Famotidine may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Famotidine may increase the QTc-prolonging activities of Clarithromycin. Approved Clotrimazole The metabolism of Famotidine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine Famotidine may increase the QTc-prolonging activities of Clozapine. Approved Crizotinib Famotidine may increase the QTc-prolonging activities of Crizotinib. Approved Cysteamine The therapeutic efficacy of Cysteamine can be decreased when used in combination with Famotidine. Approved, Investigational Dabrafenib The serum concentration of Famotidine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dasatinib Famotidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Delavirdine Famotidine can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Dexmethylphenidate Famotidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Investigational Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Famotidine. Approved, Illicit Diethylpropion Diethylpropion may decrease the sedative activities of Famotidine. Approved, Illicit Disopyramide Famotidine may increase the QTc-prolonging activities of Disopyramide. Approved Dofetilide Famotidine may increase the QTc-prolonging activities of Dofetilide. Approved, Investigational Dolasetron Famotidine may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Famotidine may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Dronedarone Famotidine may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Famotidine may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Efavirenz The metabolism of Famotidine can be decreased when combined with Efavirenz. Approved, Investigational Eliglustat Famotidine may increase the QTc-prolonging activities of Eliglustat. Approved Erlotinib The serum concentration of Erlotinib can be decreased when it is combined with Famotidine. Approved, Investigational Erythromycin Famotidine may increase the QTc-prolonging activities of Erythromycin. Approved, Investigational, Vet Approved Escitalopram Famotidine may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Eslicarbazepine acetate The metabolism of Famotidine can be decreased when combined with Eslicarbazepine acetate. Approved Esomeprazole The metabolism of Famotidine can be decreased when combined with Esomeprazole. Approved, Investigational Etravirine The metabolism of Famotidine can be decreased when combined with Etravirine. Approved Ferric Carboxymaltose Famotidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Ferric pyrophosphate Famotidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Experimental Flecainide Famotidine may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Fluconazole The metabolism of Famotidine can be decreased when combined with Fluconazole. Approved, Investigational Fluoxetine Famotidine may increase the QTc-prolonging activities of Fluoxetine. Approved, Vet Approved Flupentixol Famotidine may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluvoxamine The metabolism of Famotidine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The serum concentration of Fosamprenavir can be decreased when it is combined with Famotidine. Approved Fosphenytoin The metabolism of Famotidine can be increased when combined with Fosphenytoin. Approved, Investigational Gadobenic acid Famotidine may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gefitinib The serum concentration of Gefitinib can be decreased when it is combined with Famotidine. Approved, Investigational Gemfibrozil The metabolism of Famotidine can be decreased when combined with Gemfibrozil. Approved Gemifloxacin Famotidine may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gepefrine Gepefrine may decrease the sedative activities of Famotidine. Experimental Goserelin Famotidine may increase the QTc-prolonging activities of Goserelin. Approved Granisetron Famotidine may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Haloperidol Famotidine may increase the QTc-prolonging activities of Haloperidol. Approved Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine. Approved, Investigational Hydroxyamphetamine Hydroxyamphetamine may decrease the sedative activities of Famotidine. Approved Ibutilide Famotidine may increase the QTc-prolonging activities of Ibutilide. Approved Iloperidone Famotidine may increase the QTc-prolonging activities of Iloperidone. Approved Indinavir The serum concentration of Indinavir can be decreased when it is combined with Famotidine. Approved Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Famotidine. Approved Iron Famotidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Iron Dextran Famotidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Vet Approved Iron saccharate Famotidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Isoniazid The metabolism of Famotidine can be decreased when combined with Isoniazid. Approved, Investigational Itraconazole The serum concentration of Itraconazole can be decreased when it is combined with Famotidine. Approved, Investigational Ketoconazole The serum concentration of Ketoconazole can be decreased when it is combined with Famotidine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be decreased when it is combined with Famotidine. Approved Lenvatinib Famotidine may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Leuprolide Famotidine may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levofloxacin Famotidine may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Famotidine. Approved, Investigational Lobeglitazone The metabolism of Famotidine can be decreased when combined with Lobeglitazone. Approved, Investigational Lopinavir The metabolism of Famotidine can be increased when combined with Lopinavir. Approved Luliconazole The serum concentration of Famotidine can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Famotidine can be decreased when it is combined with Lumacaftor. Approved Lumefantrine Famotidine may increase the QTc-prolonging activities of Lumefantrine. Approved Mephedrone Mephedrone may decrease the sedative activities of Famotidine. Investigational Mephentermine Mephentermine may decrease the sedative activities of Famotidine. Approved Mesalazine The therapeutic efficacy of Mesalazine can be decreased when used in combination with Famotidine. Approved Methadone Famotidine may increase the QTc-prolonging activities of Methadone. Approved Methamphetamine Methamphetamine may decrease the sedative activities of Famotidine. Approved, Illicit Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Famotidine. Experimental Methylphenidate Famotidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Investigational Midomafetamine Midomafetamine may decrease the sedative activities of Famotidine. Experimental, Illicit, Investigational Mifepristone Mifepristone may increase the QTc-prolonging activities of Famotidine. Approved, Investigational MMDA MMDA may decrease the sedative activities of Famotidine. Experimental, Illicit Moclobemide The metabolism of Famotidine can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Famotidine can be decreased when combined with Modafinil. Approved, Investigational Moxifloxacin Famotidine may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Nelfinavir The serum concentration of Nelfinavir can be decreased when it is combined with Famotidine. Approved Nicardipine The metabolism of Famotidine can be decreased when combined with Nicardipine. Approved, Investigational Nilotinib The serum concentration of Nilotinib can be decreased when it is combined with Famotidine. Approved, Investigational Ofloxacin Famotidine may increase the QTc-prolonging activities of Ofloxacin. Approved Omeprazole The metabolism of Famotidine can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Ondansetron Famotidine may increase the QTc-prolonging activities of Ondansetron. Approved Paliperidone Famotidine may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Famotidine may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Pantoprazole The metabolism of Famotidine can be decreased when combined with Pantoprazole. Approved Pazopanib Famotidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Pentamidine Famotidine may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Perflutren Famotidine may increase the QTc-prolonging activities of Perflutren. Approved Phentermine Phentermine may decrease the sedative activities of Famotidine. Approved, Illicit Phenytoin The metabolism of Famotidine can be increased when combined with Phenytoin. Approved, Vet Approved Pimozide Famotidine may increase the QTc-prolonging activities of Pimozide. Approved Posaconazole The serum concentration of Posaconazole can be decreased when it is combined with Famotidine. Approved, Investigational, Vet Approved Primaquine Famotidine may increase the QTc-prolonging activities of Primaquine. Approved Procainamide Famotidine may increase the QTc-prolonging activities of Procainamide. Approved Promazine Famotidine may increase the QTc-prolonging activities of Promazine. Approved, Vet Approved Propafenone Famotidine may increase the QTc-prolonging activities of Propafenone. Approved Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Famotidine. Approved Quetiapine Famotidine may increase the QTc-prolonging activities of Quetiapine. Approved Quinidine Famotidine may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Famotidine may increase the QTc-prolonging activities of Quinine. Approved Rifampicin The metabolism of Famotidine can be increased when combined with Rifampicin. Approved Rilpivirine The serum concentration of Rilpivirine can be decreased when it is combined with Famotidine. Approved Risedronate Famotidine can cause an increase in the absorption of Risedronate resulting in an increased serum concentration and potentially a worsening of adverse effects. Approved, Investigational Ritobegron Ritobegron may decrease the sedative activities of Famotidine. Investigational Rucaparib The metabolism of Famotidine can be decreased when combined with Rucaparib. Approved, Investigational Saquinavir The serum concentration of Saquinavir can be increased when it is combined with Famotidine. Approved, Investigational Sertraline The metabolism of Famotidine can be decreased when combined with Sertraline. Approved Sotalol Famotidine may increase the QTc-prolonging activities of Sotalol. Approved Stiripentol The metabolism of Famotidine can be decreased when combined with Stiripentol. Approved Sulfisoxazole Famotidine may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Telavancin Famotidine may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Famotidine may increase the QTc-prolonging activities of Telithromycin. Approved Tetrabenazine Famotidine may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Thioridazine Famotidine may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Ticlopidine The metabolism of Famotidine can be decreased when combined with Ticlopidine. Approved Topiramate The metabolism of Famotidine can be decreased when combined with Topiramate. Approved Toremifene Famotidine may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tranylcypromine The metabolism of Famotidine can be decreased when combined with Tranylcypromine. Approved, Investigational Vandetanib Famotidine may increase the QTc-prolonging activities of Vandetanib. Approved Varenicline The serum concentration of Varenicline can be increased when it is combined with Famotidine. Approved, Investigational Vemurafenib Famotidine may increase the QTc-prolonging activities of Vemurafenib. Approved Voriconazole The metabolism of Famotidine can be decreased when combined with Voriconazole. Approved, Investigational Ziprasidone Famotidine may increase the QTc-prolonging activities of Ziprasidone. Approved Zucapsaicin The metabolism of Famotidine can be decreased when combined with Zucapsaicin. Approved, Investigational Zuclopenthixol Famotidine may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Avoid alcohol.
- Limit caffeine intake.
- Take without regard to meals, food may slightly increase the product's bioavailability.
References
- Synthesis Reference
Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.
US5021582- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001919
- KEGG Drug
- D00318
- PubChem Compound
- 3325
- PubChem Substance
- 46507397
- ChemSpider
- 3208
- BindingDB
- 50036754
- ChEBI
- 4975
- ChEMBL
- CHEMBL902
- Therapeutic Targets Database
- DAP000341
- PharmGKB
- PA449586
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Famotidine
- ATC Codes
- A02BA03 — Famotidine
- A02BA — H2-receptor antagonists
- A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- AHFS Codes
- 56:28.12 — Histamine H2-antagonists
- FDA label
- Download (1.05 MB)
- MSDS
- Download (73.8 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Lupin ltd
- Navinta llc
- Salix pharmaceuticals inc
- Akorn strides llc
- Apotex inc richmond hill
- Apothecon inc div bristol myers squibb
- App pharmaceuticals llc
- Baxter healthcare corp anesthesia and critical care
- Baxter healthcare corp
- Bedford laboratories div ben venue laboratories inc
- Hospira inc
- Ben venue laboratories inc
- Claris lifesciences ltd
- Abbott laboratories
- Baxter healthcare internati0nal specialty therapies div
- Merck research laboratories div merck co inc
- L perrigo co
- Schwarz pharma inc
- Actavis elizabeth llc
- Alembic ltd
- Apotex inc
- Carlsbad technology inc
- Dr reddys laboratories ltd
- Genpharm inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Mutual pharmaceutical co inc
- Mylan pharmaceuticals inc
- Perrigo co
- Ranbaxy laboratories inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Wockhardt ltd
- Wockhardt americas inc
- Packagers
- Advanced Pharmaceutical Services Inc.
- Akorn Inc.
- Amerisource Health Services Corp.
- APP Pharmaceuticals
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Baxter International Inc.
- Bedford Labs
- Ben Venue Laboratories Inc.
- Bryant Ranch Prepack
- Cardinal Health
- Carlsbad Technology Inc.
- Chain Drug
- Corepharma LLC
- CVS Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Doctor Reddys Laboratories Ltd.
- H.J. Harkins Co. Inc.
- Heartland Repack Services LLC
- Hospira Inc.
- Ivax Pharmaceuticals
- Johnson & Johnson Healthcare
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Legacy Pharmaceuticals Packaging LLC
- Lupin Pharmaceuticals Inc.
- Major Pharmaceuticals
- Mckesson Corp.
- Medisca Inc.
- Merck & Co.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Northstar Rx LLC
- Nucare Pharmaceuticals Inc.
- PCA LLC
- PD-Rx Pharmaceuticals Inc.
- Perrigo Co.
- Pharmaceutical Utilization Management Program VA Inc.
- Pharmedium
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepackage Specialists
- Prepak Systems Inc.
- Rebel Distributors Corp.
- Redpharm Drug
- Remedy Repack
- Salix Pharmaceuticals
- Sandhills Packaging Inc.
- Southwood Pharmaceuticals
- Strides Arcolab Limited
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Walgreen Co.
- Watson Pharmaceuticals
- Wockhardt Ltd.
- Yung Shin Pharmaceutical Industry Ltd.
- Zydus Pharmaceuticals
- Dosage forms
Form Route Strength Tablet, chewable Oral Tablet, coated Oral For suspension Oral 40 mg/5mL Injection Intravenous 10 mg/mL Injection, solution Intravenous 10 mg/mL Injection, solution Intravenous 2 mg/mL Injection, solution Intravenous 20 mg/50mL Powder, for solution Oral 40 mg/5mL Powder, for suspension Oral 40 mg/5mL Tablet Oral 10 mg/1 Tablet Oral 40 mg/1 Tablet, film coated Oral 40 mg/1 Tablet, film coated, extended release Oral 10 mg/1 Solution Intravenous 10 mg Tablet Oral 20 mg/1 Tablet Oral 10 mg Tablet, chewable Oral 20 mg/1 Tablet, film coated Oral 20 mg/1 Tablet, film coated Oral 10 mg/1 Tablet Oral 20 mg Tablet Oral 40 mg Tablet, coated Oral 10 mg/1 - Prices
Unit description Cost Unit Pepcid 30 40 mg tablet Bottle 125.5USD bottle Pepcid 40 mg/5ml Suspension 50ml Bottle 123.88USD bottle Pepcid 30 20 mg tablet Bottle 64.13USD bottle Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle 10.15USD bottle Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle 9.23USD bottle Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle 7.99USD bottle Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle 7.99USD bottle Famotidine 40 mg tablet 3.43USD tablet Pepcid 40 mg tablet 3.02USD tablet Famotidine powder 2.74USD g Famotidine 20 mg tablet 1.76USD tablet Pepcid 20 mg tablet 1.6USD tablet Apo-Famotidine 40 mg Tablet 1.11USD tablet Mylan-Famotidine 40 mg Tablet 1.11USD tablet Novo-Famotidine 40 mg Tablet 1.11USD tablet Nu-Famotidine 40 mg Tablet 1.11USD tablet Pepcid ac 10 mg tablet 0.72USD tablet Famotidine 40 mg/4 ml vial 0.71USD ml Famotidine 500 mg/50 ml vial 0.71USD ml Apo-Famotidine 20 mg Tablet 0.62USD tablet Mylan-Famotidine 20 mg Tablet 0.62USD tablet Novo-Famotidine 20 mg Tablet 0.62USD tablet Nu-Famotidine 20 mg Tablet 0.62USD tablet Pepcid ac 20 mg tablet 0.58USD tablet Famotidine-ns 20 mg/10 ml syrg 0.54USD ml Pepcid ac 10 mg gelcap 0.48USD capsule Pepcid complete tablet chew 0.4USD tablet Famotidine 20 mg/2 ml vial 0.36USD ml Famotidine 10 mg/ml vial 0.28USD ml CVS Pharmacy acid controller 20 mg tablet 0.24USD tablet CVS Pharmacy acid controller tablet 0.24USD tablet Acid reducer 20 mg tablet 0.22USD tablet Acid controller 10 mg tablet 0.21USD tablet Mylanta gas 125 mg tablet chew 0.16USD tablet Acid reducer 10 mg tablet 0.15USD tablet Famotidine 10 mg tablet 0.15USD tablet Famotidine 20 mg piggyback 0.13USD ml Mylanta gelcap 0.12USD capsule Mylanta ultimate-strength tablet 0.07USD tablet Mylanta ultra chew tablet 0.06USD tablet Pv acid reducer 10 mg tablet 0.05USD tablet Mylanta liq 0.02USD ml Mylanta supreme antacid liq 0.02USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5075114 No 1993-05-23 2010-05-23 US CA2178277 No 2000-11-14 2016-06-05 Canada CA2052679 No 1997-12-02 2011-08-21 Canada US6221392 No 1998-04-09 2018-04-09 US US6024981 No 1998-04-09 2018-04-09 US US5854267 Yes 1996-06-29 2016-06-29 US US6814978 Yes 2002-02-26 2022-02-26 US US5989588 Yes 1998-03-30 2018-03-30 US US8067451 No 2006-07-18 2026-07-18 US US8501228 No 2006-07-18 2026-07-18 US US8318202 No 2006-07-18 2026-07-18 US US8449910 No 2006-07-18 2026-07-18 US US8309127 No 2006-07-18 2026-07-18 US US8067033 No 2006-07-18 2026-07-18 US US5667794 Yes 1995-11-02 2015-11-02 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 163.5 °C PhysProp water solubility 1000 mg/L (at 20 °C) MERCK INDEX (1996) logP -0.64 ISLAM,MS & NARURKAR,MM (1993) - Predicted Properties
Property Value Source Water Solubility 0.271 mg/mL ALOGPS logP -0.2 ALOGPS logP -2 ChemAxon logS -3.1 ALOGPS pKa (Strongest Acidic) 9.29 ChemAxon pKa (Strongest Basic) 8.38 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 175.83 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 80.46 m3·mol-1 ChemAxon Polarizability 32.02 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9156 Blood Brain Barrier + 0.9382 Caco-2 permeable - 0.8957 P-glycoprotein substrate Non-substrate 0.5839 P-glycoprotein inhibitor I Non-inhibitor 0.9044 P-glycoprotein inhibitor II Non-inhibitor 0.8701 Renal organic cation transporter Non-inhibitor 0.6802 CYP450 2C9 substrate Non-substrate 0.7898 CYP450 2D6 substrate Non-substrate 0.9115 CYP450 3A4 substrate Non-substrate 0.7558 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9297 Ames test Non AMES toxic 0.5827 Carcinogenicity Non-carcinogens 0.9182 Biodegradation Not ready biodegradable 0.9324 Rat acute toxicity 1.9523 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8366 hERG inhibition (predictor II) Inhibitor 0.6481
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Thiazoles
- Direct Parent
- 2,4-disubstituted thiazoles
- Alternative Parents
- Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxides show 1 more
- Substituents
- 2,4-disubstituted 1,3-thiazole / Organic sulfuric acid or derivatives / Heteroaromatic compound / Guanidine / Amidine / Azacycle / Dialkylthioether / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Sulfenyl compound show 9 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
- Gene Name
- HRH2
- Uniprot ID
- P25021
- Uniprot Name
- Histamine H2 receptor
- Molecular Weight
- 40097.65 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Fukuda M, Tanaka S, Suzuki S, Kusama K, Kaneko T, Sakashita H: Cimetidine induces apoptosis of human salivary gland tumor cells. Oncol Rep. 2007 Mar;17(3):673-8. [PubMed:17273750]
- Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495]
- Kesiova M, Alexandrova A, Yordanova N, Kirkova M, Todorov S: Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues. Pharmacol Rep. 2006 Mar-Apr;58(2):221-8. [PubMed:16702624]
- Lesclous P, Schramm F, Gallina S, Baroukh B, Guez D, Saffar JL: Histamine mediates osteoclastic resorption only during the acute phase of bone loss in ovariectomized rats. Exp Physiol. 2006 May;91(3):561-70. Epub 2006 Mar 2. [PubMed:16513821]
- Amagase K, Okabe S: On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. J Pharmacol Sci. 2003 Jun;92(2):124-36. [PubMed:12832840]
- Weydert JA, Ball TM, Davis MF: Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003 Jan;111(1):e1-11. [PubMed:12509588]
- Miyata K, Kamato T, Nishida A, Honda K: Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol. 1991 Feb;55(2):211-22. [PubMed:2067140]
- Leurs R, Brozius MM, Smit MJ, Bast A, Timmerman H: Effects of histamine H1-, H2- and H3-receptor selective drugs on the mechanical activity of guinea-pig small and large intestine. Br J Pharmacol. 1991 Jan;102(1):179-85. [PubMed:1646056]
- Inan A, Sen M, Surgit O, Ergin M, Bozer M: Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo). 2009;64(6):567-70. [PubMed:19578661]
- Ojiako K, Shingala H, Schorr C, Gerber DR: Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. Am J Crit Care. 2008 Mar;17(2):142-7. [PubMed:18310651]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Quaternary ammonium group transmembrane transporter activity
- Specific Function
- Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
- Gene Name
- SLC22A2
- Uniprot ID
- O15244
- Uniprot Name
- Solute carrier family 22 member 2
- Molecular Weight
- 62579.99 Da
References
- Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
- Gene Name
- SLC22A8
- Uniprot ID
- Q8TCC7
- Uniprot Name
- Solute carrier family 22 member 8
- Molecular Weight
- 59855.585 Da
References
- Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291]
- Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168]
- Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
Drug created on June 13, 2005 07:24 / Updated on June 23, 2018 21:17